Dutch biotech company Pharming has announced positive results from ongoing open-label studies with recombinant human C1 inhibitor (Rhucin) for the treatment of acute attacks of Hereditary Angioedema (HAE).
The positive results are from the treatment of 123 acute HAE attacks in 64 patients with different doses of Rhucin in the ongoing European and North American open-label studies.
Rhucin has been consistently safe and effective in patients receiving up to nine treatments with no evidence of decreased response to the study drug. Importantly, all seven serious laryngeal attacks treated in these studies responded rapidly to Rhucin.
Dr. Bruno Giannetti, Chief Operations Officer at Pharming said that the clinical benefits of Rhucin has no adverse reactions or immune responses. Furthermore, the total number of treatments has substantially increased; including the successful treatment of serious potentially life-threatening laryngeal attacks.